U.S., Sept. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07193810) titled 'A Study of CC312 for Relapsed/Refractory Autoimmune Diseases' on Sept. 15.
Brief Summary: This study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or refractory autoimmune diseases.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
SLE - Systemic Lupus Erythematosus
IIM- Idiopathic Inflammatory Myopathies
SSc-Systemic Sclerosis
Intervention:
BIOLOGICAL: CC312
CC312 is administered twice weekly (BIW) on Day 1 and Day 4 of each week for a 4-week tr...